Efficacy of Rosuvastatin Combined with Conventional Treatment in the Patients with Acute Cerebral In-farction and Influence on Serum Levels of VS-2, sICAM-1and MMp2
- VernacularTitle:瑞舒伐他汀联合常规治疗急性脑梗死疗效及对患者血清 VS-2、sICAM-1和 MMp2水平影响
- Author:
Li WANG
;
Yanlong CHEN
;
Zhaoli XU
- Publication Type:Journal Article
- Keywords:
Rosuvastatin;
Acute cerebral infarction;
Matrix metalloproteinase 2;
Vasostatin-2;
sICAM-1
- From:
China Pharmacist
2016;19(6):1120-1122,1123
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the efficacy of rosuvastatin combined with the conventional treatment in the patients with acute cerebral infarction (ACI) and the influence on the serum levels of MMp2, vasostatin-2 and sICAM-1.Methods:Totally 136 patients with ACI were randomly divided into the routine treatment group and the rosuvastatin group with 68 ones in each .The patients in the routine treatment group were treated with the conventional treatment , and those in the rosuvastatin group were treated with rosuvastatin additionally.The treatment course was 15 days.The efficacy, adverse drug reactions and the changes of MMp 2, vasostatin-2 and sI-CAM-1 in the two groups were compared .Results:The effective rate was 92.65%in rosuvastatin group and that was 77.94%in the routine treatment group, and the difference was statistically significant (P<0.05).After the treatment, the levels of MMp2, vasosta-tin-2 and sICAM-1 for the mild, medium and severe types in the two groups were significantly decreased when compared with those be -fore the treatment (P<0.05), and the decrease for the same type in rosuvastatin group was more notable than that in the routine treat -ment group (P<0.05).The indices for different subgroups with various infarcts in rosuvastatin group were all lower than those for the same subgroup in the routine treatment group (P<0.05).The incidence of adverse drug reactions (ADR) in two group was no signifi-cant difference (P>0.05).Conclusion:Rosuvastatin used in the patients with ACI has better clinical efficacy than the routine treat-ment, which can reduce the levels of MMp 2, vasostatin-2 and sICAM-1 and is worthy of clinical promotion .
